Eight lncRNAs in Hepatocellular Carcinoma: Potential as Diagnostic and Therapeutic Candidates and Validation Challenges
Background: Why seek new candidates for liver cancer diagnosis and treatment?
A review has examined the regulatory mechanisms and diagnostic and therapeutic potential of eight long noncoding RNAs (lncRNAs) implicated in hepatocellular carcinoma (HCC). The researchers reviewed the literature and computationally predicted RNA interaction networks for six of the eight. The review considers both the evidence for each candidate and the validation still needed before clinical application.
Early detection and overcoming treatment resistance remain difficult in HCC. Alpha-fetoprotein (AFP), an established blood marker, is insufficient on its own for detecting early-stage cancer, and treatment responses vary among patients. These limitations have drawn attention to lncRNAs—regulatory RNAs longer than 200 nucleotides—as potential biomarkers and therapeutic targets. They participate in the regulation of gene expression and the tumor microenvironment.
The researchers searched the literature through January 2026 and focused on CYTOR, UCA1, MALAT1, SPRY4-IT1, uc001ncr, AF085935, HULC, and HOTAIR. These candidates have been implicated in cancer-cell proliferation, invasion, metastasis, and treatment resistance, although their levels of validation differ.
Key findings: Separating regulatory mechanisms from computational predictions
The review describes how lncRNAs regulate cancer-related signaling in different ways. HOTAIR and SPRY4-IT1 act as scaffolds that guide chromatin-regulating complexes to specific locations, while UCA1 and MALAT1 are described as participating in post-transcriptional regulation, including interactions with microRNAs (miRNAs). Relevant pathways include PI3K/AKT/mTOR, Wnt/β-catenin, and pathways associated with epithelial–mesenchymal transition (EMT). However, lncRNAs can promote or suppress tumors depending on the cellular context, so increased expression alone cannot establish whether an lncRNA is a suitable therapeutic target.
Using DIANA-LncBase v3 and TargetScan v8.0, the researchers constructed a competing endogenous RNA (ceRNA) network linking six lncRNAs with miRNAs and messenger RNAs (mRNAs). uc001ncr and AF085935 were excluded because reliable data on their miRNA interactions were insufficient in the databases queried.
The ceRNA hypothesis proposes that an lncRNA can bind a miRNA and thereby relieve repression of an mRNA targeted by that same miRNA. However, the links in this network are computational predictions and require experimental validation in HCC models. In particular, researchers must determine whether the relative amounts of lncRNA, miRNA, and target mRNA inside actual cells support this mechanism. Whether results from overexpression experiments also hold at physiological expression levels remains a separate question.
Implications and outlook: The validation gap between blood markers and therapeutic targets
Associations between HULC, HOTAIR, and MALAT1 and clinical outcomes have been reported across multiple patient cohorts. By contrast, evidence for uc001ncr and AF085935 relies on relatively small cohorts and incomplete mechanistic data. Some candidates can be detected in blood, but sample processing, exosome isolation, and normalization of measurements have not been standardized. It also remains insufficiently established how much adding these candidates to AFP would improve diagnostic performance.
Treatment approaches discussed include small interfering RNA (siRNA), antisense oligonucleotides (ASOs), and CRISPR-based expression regulation. According to the review, there is no phase 3 clinical evidence for lncRNA-targeted drugs in HCC. Delivery into tumor cells, off-target RNA suppression, and hepatotoxicity risks in patients with pre-existing liver disease also need to be addressed.
Single-cell RNA sequencing and spatial transcriptomics are being used to identify the expressing cell populations and their locations that bulk-tissue averages can obscure. The review stresses the need to apply these approaches systematically. Identifying whether a particular lncRNA acts in tumor cells or in surrounding immune or stromal cells would clarify the rationale for selecting it as a target.
Sources: Full text of the review, article bibliographic information and abstract.
Hepatocellular carcinoma (HCC) remains the third leading cause of cancer-related mortality worldwide, with limited treatment efficacy and poor prognosis, particularly in advanced-stage disease. Despite progress in diagnostic imaging and systemic therapies, early detection and effective targeted interventions remain major clinical challenges. Long non-coding RNAs (lncRNAs), a class of regulatory RNA molecules exceeding 200 nucleotides in length, have emerged as essential regulators of oncogenic signaling, metabolism, and tumor microenvironment in HCC. This review provides a comprehensive overview of the molecular mechanisms, biological functions, and clinical relevance of key lncRNAs involved in HCC progression. We summarize the dual roles of lncRNAs as oncogenic drivers and tumor suppressors, with particular emphasis on oncogenic lncRNAs including CYTOR, UCA1, MALAT1, SPRY4-IT1, uc001ncr, AF085935, HULC, and HOTAIR. Their regulatory functions are discussed within major cancer-associated signaling networks, including the PI3K/AKT/mTOR, Wnt/β-catenin, TGF-β/NF-κB, and EMT-associated pathways. Furthermore, each lncRNA is discussed in the context of its expression pattern, endogenous RNA (ceRNA) interactions, molecular partners, and functional contributions to cellular proliferation, invasion, metastasis, angiogenesis, immune modulation, and therapeutic resistance. In addition, we explore the emerging potential of lncRNAs as minimally invasive diagnostic and prognostic biomarkers, owing to their stability and detectability in tissue and circulating biofluids. We also discuss recent advances in RNA- targeted therapeutic strategies, including RNA interference, siRNA-mediated silencing, antisense oligonucleotides, and CRISPR-based genome editing approaches. Collectively, this review highlights the importance of integrating lncRNA expression signatures into personalized HCC management and the promising role of lncRNA-based diagnostics and therapeutics in transforming the future.
This review can help prioritize validation of diagnostic candidates and therapeutic targets. For example, prospective studies evaluating circulating lncRNAs could analyze them alongside AFP and imaging and assess whether their added diagnostic value is maintained in patients with chronic hepatitis or cirrhosis. Comparing results across institutions first requires standardized sample processing and normalization methods.
Development of siRNA or ASO therapies requires more than selecting candidates with high expression. Researchers must also verify which cell populations actually express them, their function under physiological conditions, delivery into tumors, and hepatotoxicity. The candidate list and differences in evidence levels offer a starting point for designing such studies. The review does not demonstrate an effect that changes current care or improves patient survival.